A Study of LY4395089 and Mirikizumab for Crohn's Disease
This study is looking at two medications for adults with moderately to severely active Crohn's disease (CD). Researchers want to see how safe and effective LY4395089 (taken by mouth) is when given along with Mirikizumab (given by IV or under the skin), compared to Mirikizumab alone. You may be able to join if you are between 18 and 80 years old and meet other specific health requirements. The main goal is to see how many participants achieve an endoscopic response (improvement seen during an endoscopy) by about 12 weeks. The study plans to enroll 60 people, but its current recruitment status is unclear. The study will last about 62 weeks.
- Study design
- This is an interventional study planning to enroll 60 adult participants. It is part of a larger master protocol.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary endpoint is measured up to Week 12, and the study lasts approximately 62 weeks.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease
At a glance
Conditions
Where it's being run
70 sites across 20 statesStudy leadership
- Contact Lilly at 1-877-CTLILLY (1-877-285-4559) or · STUDY_DIRECTOR · Eli Lilly and Company
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Percentage of Participants with Crohn's Disease who Achieve Endoscopic ResponseBaseline, Up to Week 12
The percentage of participants who achieve endoscopic response at week 12 of Study Period 1.